<DOC>
	<DOCNO>NCT00841113</DOCNO>
	<brief_summary>To compare safety efficacy abarelix versus goserelin plus bicalutamide patient advance metastatic prostate cancer .</brief_summary>
	<brief_title>Abarelix Versus Goserelin Plus Bicalutamide Patients With Advanced Metastatic Prostate Cancer</brief_title>
	<detailed_description>Inclusion Criteria - Males 18 document advanced metastatic prostate cancer Outcome measure - Comparative castration rate one week start therapy - Degree testosterone surge first month treatment . - Maintenance medical castration one year therapy . - Comparison treatment QTc prolongation</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Abarelix</mesh_term>
	<criteria>Histologically proven prostate cancer previously treat hormone Evidance advance disease metastasis Life expentancy least 3 month Normal serum testosterone level Written inform consent Previous endocrine cytoxic theapy prostate cancer Known tumour complication prostate cancer owuld require immediate treatment Another malignancy basal cell cancer History significant drug hypersensitivity either LHRH agonists GnRH antagonist . Congenital acquire coagulation disorder contraindicate intramuscular injection Pagets disease bone QTcB &gt; 450 msec Day 14</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Advanced</keyword>
	<keyword>Metastatic</keyword>
</DOC>